SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
NCT04246528 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 169
Last updated 2025-09-09
Summary
The Scleroderma Patient-centered Intervention Network (SPIN) is an organization established by researchers, health care providers, and people living with scleroderma (systemic sclerosis; SSc) from Canada, the United States, Mexico, Australia, France, Spain, and the United Kingdom. The objectives of SPIN are (1) to assemble a large cohort of SSc patients who complete outcome assessments regularly in order to learn more about important problems faced by people living with SSc and (2) to develop and test a series of internet-based interventions to help patients manage problems related to SSc, including a self-management program (SPIN-SELF Program).
The SPIN-SELF Program was designed by SPIN members based on key tenets of behaviour change that have been successfully incorporated in programs for more common diseases and on patient input. It utilizes social modelling through educational videos of SSc patients describing their challenges and what they have done to cope with SSc, as well as videos teaching key self-management techniques. After an introduction to self-management and instructions on how to navigate the program, patients will have access to modules that are most relevant to their symptoms and disease management challenges. The program's modules address (1) pain; (2) skin care, finger ulcers, and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) emotions and stress; (8) body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
The proposed study is a feasibility trial with progression to full-scale randomized controlled trial (RCT), depending on whether stoppage criteria are met, of the SPIN Self-Management Program. The SPIN-SELF Program was previously feasibility tested as an online only, self-help intervention. However, uptake was low, thus the investigators have moved to a group-based format. SPIN-SELF participants randomized to intervention will access and use online self-management material, and this will be supported by videoconference group sessions, led by trained peer facilitators.
In the SPIN-SELF feasibility trial with progression to full-scale trial, the investigators will evaluate the disease management self-efficacy of participants who use SPIN-SELF compared to usual care. Eligible SPIN Cohort participants and externally recruited participants, with low disease-management self-efficacy, will be randomized to the SPIN-SELF Program or to usual care only. In the feasibility portion, 40 eligible participants will be randomized. Unless the trial team determines, based on stoppage criteria, that trial procedures need important modifications thereby re-setting the full scale trial as a new trial, the outcome data of the participants in the feasibility portion will be utilized in the analyses of the full-scale trial. In the full-scale RCT, 524 participants will be randomized.
Conditions
- Scleroderma
- Systemic Sclerosis
Interventions
- BEHAVIORAL
-
SPIN-SELF Program
The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
Sponsors & Collaborators
-
Lady Davis Institute
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-09-15
- Primary Completion
- 2025-05-01
- Completion
- 2025-05-01
Countries
- Canada
Study Locations
More Related Trials
-
Taking Charge of Systemic Sclerosis
NCT02494401 ·Status: COMPLETED ·Phase: NA
-
Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1
NCT06373263 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention
NCT04588714 ·Status: COMPLETED ·Phase: NA
-
Making it Work Program for Systemic Sclerosis
NCT06338722 ·Status: COMPLETED ·Phase: NA
-
RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and Fatigue
NCT04908943 ·Status: COMPLETED ·Phase: NA
-
6-minute Pegboard Ring Test in Patients with Scleroderma
NCT06588959 ·Status: NOT_YET_RECRUITING
-
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
NCT05726630 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
NCT00318188 ·Status: COMPLETED ·Phase: NA
-
Exercise in People With Systemic Sclerosis
NCT05234671 ·Status: COMPLETED ·Phase: NA
-
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
NCT06297096 ·Status: RECRUITING ·Phase: PHASE3
-
Self-management Telehealth Program for Scleroderma
NCT06990386 ·Status: COMPLETED ·Phase: NA
-
EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS
NCT02206672 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Aesthetic Impact in Patients With Systemic Sclerosis
NCT03271320 ·Status: COMPLETED
-
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
NCT01881529 ·Status: COMPLETED
-
Prospective Cohort of Patients With Systemic Sclerosis at Brest University Hospital With Biobanking
NCT05532865 ·Status: RECRUITING
-
Delving Into Participation Trends of Scleroderma Clinical Trials
NCT06264492 ·Status: NOT_YET_RECRUITING
-
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
NCT02349009 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis
NCT01813279 ·Status: COMPLETED ·Phase: NA
-
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
NCT01895244 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
NCT00946699 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis
NCT01858259 ·Status: UNKNOWN
-
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
NCT05177380 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
NCT02921971 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580 ·Status: COMPLETED ·Phase: PHASE2
-
Stress, Scleroderma and Quality of Life
NCT05617066 ·Status: COMPLETED ·Phase: NA